Lactoferrin: a multifunctional immunoregulatory protein?

Brock, Jeremy H.

doi:10.1016/0167-5699(95)80016-6

Cited by 215 publications

(148 citation statements)

References 9 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…Lactoferrin possesses a wide range of immunomodulatory activities [17][18][19] [20] [21] including promotion of the T-cell dominated DTH response towards BCG antigens [22,23], The ability of lactoferrin to enhance the generation of antigen specific DTH responses suggests that lactoferrin could promote development of specific T-cell responses against a complex antigen, such as BCG [24,25] The development of T-cell helper type 1 (T H 1) immunity is, in part, regulated by production of IL-12 [26,27]. A variety of in vivo studies have shown lactoferrin capable of increasing production of IL-12 [28][29][30].…”

Section: Introductionmentioning

confidence: 99%

Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis

Hwang

Wilk

Budnicka

et al. 2007

Vaccine

View full text Add to dashboard Cite

Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a disease with world wide consequences, affecting nearly a third of the world's population. The established vaccine for TB, an attenuated strain of Mycobacterium bovis Calmette Guerin (BCG), has existed since 1921. Lactoferrin, an iron binding protein found in mucosal secretions and granules of neutrophils was hypothesized to be an ideal adjuvant to enhance the efficacy of the BCG vaccine, specifically because of previous reports of lactoferrin enhancement of IL-12 production from macrophages infected with BCG. Different vaccination protocols were investigated for generation of host protective responses against MTB infection using lactoferrin admixed to the BCG vaccine. Resulting effects demonstrate that BCG/lactoferrin increased host protection against MTB infection by decreasing organ bacterial load and reducing lung histopathology; significant reduction in tissue CFUs and pathology were observed post challenge compared to those seen with BCG alone. Addition of lactoferrin to the vaccine led to reduced pathological damage upon subsequent infection with virulent MTB, with positive results demonstrated when admixed in oil-based vehicle (incomplete Freund's adjuvant; IFA) or when given with BCG in saline. The observed post-challenge results paralleled increasing production of IFN-γ and IL-6, but only limited changes to proinflammatory mediators TNF-α or IL-1β from BCG stimulated splenocytes. Overall, these studies indicate that lactoferrin is a useful and effective adjuvant to improve efficacy of the BCG vaccine, with potential to reduce related tissue damage and pulmonary histopathology.

show abstract

Section: Introductionmentioning

confidence: 99%

Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis

Hwang

Wilk

Budnicka

et al. 2007

Vaccine

View full text Add to dashboard Cite

show abstract

“…LF has a number of biological functions, including antimicrobial and immunomodulatory effects in vitro and in vivo (Brock, 1995;Tomita et al, 2002;Vorland, 1999). It has been reported that orally administered bovine LF reduces the number of pathogenic organisms not only in the gastrointestinal tract (Teraguchi et al, 1995;Wada et al, 1999) but also in tissues distant from the gastrointestinal tract in several animal models of infection (Abe et al, 2000;Bhimani et al, 1999;Haversen et al, 2000) and in humans with chronic hepatitis C and tinea pedis (Ishii et al, 2003;Iwasa et al, 2002;Yamauchi et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

Effect of orally administered bovine lactoferrin on the immune response in the oral candidiasis murine model

Takakura

Wakabayashi

Ishibashi

et al. 2004

Journal of Medical Microbiology

View full text Add to dashboard Cite

“…This hypothesis was strengthened by the discovery of specific LF receptors on the intestinal brush border (Mazurier et al, 1985;Kawakami & Lonnerdal, 1991), lymphocytes (Legrand et al, 1992) and possibly in hepatocytes (McAbee & Esbensen, 1991). The physiological effects of LF have been reviewed by several investigators (Baker et al, 1991;Iyer & Lonnerdal, 1993;Britigan et al, 1994;Brock, 1995;Levay & Viljoen, 1995), but the exact mechanisms of action are still unclear. Some of the observed and hypothesized effects of LF may be regulated through binding to a specific LF receptor in the small intestine.…”

Section: Introductionmentioning

confidence: 99%

Recombinant human lactoferrin ingestion attenuates indomethacin-induced enteropathy in vivo in healthy volunteers

2003

View full text Add to dashboard Cite

Objective: To determine whether recombinant human lactoferrin ingestion inhibits nonsteroidal antiinflammatory drugs (NSAID)-induced gastroenteropathy in vivo in healthy volunteers as a model for disorders associated with a rise in permeability of the stomach and the small intestine. Design: A randomized crossover dietary intervention. Subjects and interventions: In all, 15 healthy volunteers (age 2371.4 y) were tested. A sucrose and a lactulose/rhamnose (L/R) permeability test was performed to assess gastroduodenal and small intestine permeability as indicator of NSAID-induced gastroenteropathy. All subjects consumed standardized meals for 2 days. On the second day at time ¼ À24 h each subject ingested a drink containing 5 g recombinant human lactoferrin or placebo during breakfast. At t ¼ À9 h, subjects ingested the same drink with 75 mg of the NSAID indomethacin and after an overnight fast at t ¼ À1 h subjects consumed the drink and 50 mg indomethacin. After 1 h, at t ¼ 0, a permeability test was performed. Results: Small intestine permeability after indomethacin and placebo was significantly higher (L/R ratio ¼ 0.036; 0.014-0.092, Po0.05) compared to the permeability observed after ingestion of indomethacin and lactoferrin (0.028; 0.015-0.056), whereas gastroduodenal permeability did not differ between the two interventions (P ¼ 0.3). Conclusion: Oral recombinant human lactoferrin supplementation during a short-term indomethacin challenge reduced the NSAID-mediated increase in small intestinal permeability and hence may provide a nutritional tool in the treatment of hyperpermeability-associated disorders. Sponshorship: Grant and human recombinant lactoferrin donated from Agennix Inc., Houston, TX.

show abstract

Lactoferrin: a multifunctional immunoregulatory protein?

Cited by 215 publications

References 9 publications

Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis

Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis

Effect of orally administered bovine lactoferrin on the immune response in the oral candidiasis murine model

Recombinant human lactoferrin ingestion attenuates indomethacin-induced enteropathy in vivo in healthy volunteers

Contact Info

Product

Resources

About